

DESCRIPTION

Source *E. coli*-derived Gremlin protein
Accession # O60565.1

Predicted Molecular Mass 18 kDa

SPECIFICATIONS

SDS-PAGE Dimeric Gremlin 1 protein only

Activity No significant difference between EC₅₀ of reference and test lots

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Mass Spectrometry Single species with expected mass

Mycoplasma Negative when tested in both ribosomal RNA hybridization and luminescence assays

Formulation Lyophilized from acetonitrile/TFA See Certificate of Analysis for details.

PREPARATION AND STORAGE


Reconstitution Resuspend in 10 mM HCl at >100 µg/ml, prepare single use aliquots, add carrier protein if desired.

Shipping The product is shipped lyophilized at ambient temperature, on ice blocks or on dryice. Shipping at ambient temperature does not affect the bioactivity or stability of the protein. Upon receipt, store immediately at the conditions stated below.

Stability & Storage Store lyophilized protein between -20 °C and -80 °C until the date of expiry. Avoid freeze-thaw cycles.


DATA

Bioactivity



Recombinant Human/Bovine Gremlin 1, Animal-Free Protein Bioactivity Gremlin 1 activity is determined using inhibition of the BMP2 response (Qk007 #010, 52 ng/ml) from a BMP2-responsive firefly luciferase reporter in stably transfected HEK293T cells. Cells are treated (n=4) with a serial dilution of Gremlin 1 in BMP2 for 6 hours. Firefly luciferase activity is measured and normalized to the control Renilla luciferase activity. Gremlin-1 inhibits BMP-2 induced luciferase activity with an EC₅₀ = 47.9 ng/ml (2.66 nM).

SDS-PAGE



Recombinant Human/Bovine Gremlin 1, Animal-Free Protein SDS-PAGE Gremlin 1 protein migrates as a single diffuse band at ~36 kDa in non-reducing (NR) and 19 kDa in reducing (R) conditions. The protein is a non-covalent dimer and it is the dissociation of the dimer during electrophoresis which gives the characteristic diffuse band. Purified recombinant protein (7 µg) was resolved using 15% w/v SDS-PAGE in reduced (+β-mercaptoethanol, R) and non-reduced conditions (NR) and stained with Coomassie Brilliant Blue R250.

BACKGROUND

Gremlin, also known as Increased in High Glucose protein 2 (IHG-2) and Down-regulated in Mos-transformed cells protein (Drm), is a 28 kDa member of the Dan family of secreted glycoproteins (1-3). Human Gremlin is synthesized as a 184 amino acid (aa) precursor that contains a 24 aa signal sequence and a 160 aa mature region (SwissProt # O60565). The mature region contains one potential site for N-linked glycosylation (Asn 42), a cysteine-rich region, and a cysteine-knot motif (aa 94-184) whose structure is shared by members of the TGF- β superfamily (3). Post-translational modifications include glycosylation and phosphorylation (3). Gremlin exists in both secreted and membrane-associated forms (3). There are two isoforms for human Gremlin. Isoform 1 is the standard protein, and in isoform 2, there is a deletion of aa 39-79. Human Gremlin shares 99% and 86% aa sequence identity with mouse and chick Gremlin, respectively. Northern blot analysis shows that Gremlin mRNA is highly expressed in the small intestine, fetal brain and colon, and weakly expressed in adult brain, ovary, prostate, pancreas and skeletal muscle (4). Gremlin functions as a bone morphogenetic protein (BMP) antagonist. It acts by binding to, and forming heterodimers with, BMP-2, BMP-4, and BMP-7, thus preventing them from interacting with their cell surface receptors (1). This mechanism is thought to be responsible for the pattern-inducing activity of Gremlin during embryonic development (5) and to play a role in human diseases, such as diabetic nephropathy (6). However, intracellular BMP-independent mechanisms of action (7) may mediate the ability of Gremlin to suppress transformation and tumorigenesis under certain experimental conditions (8-9). Gremlin also interacts with Slit proteins and acts as an inhibitor of monocyte chemotaxis (10). In addition, Gremlin has been found to be a proangiogenic factor expressed by endothelium (9).

References:

1. Hsu, D.R. *et al.* (1998) *Mol. Cell* **1**:673.
2. McMahon, R. *et al.* (2000) *J. Biol. Chem.* **275**:9901.
3. Wordinger, R.J. *et al.* (2008) *Exp. Eye Res.* **87**:78.
4. Topol, L.Z. *et al.* (2000) *Cytogenet. Cell Genet.* **89**:79.
5. Khokha, M.K. *et al.* (2003) *Nat. Genet.* **34**:303.
6. Lappin, D.W. *et al.* (2002) *Nephrol. Dial. Transplant* **17**:65.
7. Chen, B. *et al.* (2002) *Biochem. Biophys. Res. Commun.* **295**:1135.
8. Topol, L.Z. *et al.* (1997) *Mol. Cell. Biol.* **17**:4801.
9. Stabile, H. *et al.* (2007) *Blood* **109**:1834.
10. Chen, B. *et al.* (2004) *J. Immunol.* **173**:5914.

PRODUCT SPECIFIC NOTICES

The above product was manufactured, tested and released by R&D System's contract manufacturer, Qkine Ltd, at 1 Murdoch House, Cambridge, UK, CB5 8HW. The product is for research use only and not for the diagnostic or therapeutic use.